Loading...
•
Mar 31
•/
Abivax SA Q1 2025 Earnings Report
Abivax reported increased R&D spending and a wider net loss in Q1 2025 compared to Q1 2024.
Key Takeaways
Abivax continued advancing clinical trials for obefazimod, with increased R&D expenses contributing to a higher net loss for the quarter. Despite lower revenue and financial losses, the company maintained a cash position to fund operations through Q4 2025.
Net loss increased to €52.4M due to higher R&D expenses.
Revenue declined to €994K, down from €1.19M a year earlier.
Cash and equivalents stood at €103.6M at quarter-end.
Company expects to fund operations through Q4 2025 with current resources.
Abivax SA
Abivax SA
Forward Guidance
Abivax expects to continue advancing clinical trials for obefazimod with cash runway through Q4 2025 and plans for additional financing.
Positive Outlook
- Phase 3 trials for obefazimod in UC fully enrolled as of April 2025.
- Cash reserves of €103.6M projected to fund operations through Q4 2025.
- First data readout for ABTECT Phase 3 trials expected in Q3 2025.
- Preclinical results support future combination therapies.
- ATM program allows potential access to $150M additional equity capital.
Challenges Ahead
- Net loss widened by €9.5M year-over-year.
- R&D expenses increased due to clinical trial expansion.
- Financial result turned negative due to interest and FX losses.
- Revenue decreased 16% year-over-year.
- Uncertainty remains around future funding beyond Q4 2025.